Spectrum Pharmaceuticals Company Profile (NASDAQ:SPPI)

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SPPI
  • CUSIP: 84763A10
  • Web: www.sppirx.com
Capitalization:
  • Market Cap: $663.4 million
  • Outstanding Shares: 78,523,000
Average Prices:
  • 50 Day Moving Avg: $7.16
  • 200 Day Moving Avg: $6.27
  • 52 Week Range: $3.21 - $8.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.30
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $131.68 million
  • Price / Sales: 4.78
  • Book Value: $2.77 per share
  • Price / Book: 2.90
Profitability:
  • EBIDTA: ($49,210,000.00)
  • Net Margins: -62.39%
  • Return on Equity: -24.06%
  • Return on Assets: -13.22%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 3.45%
  • Quick Ratio: 3.26%
Misc:
  • Average Volume: 772,254 shs.
  • Beta: 1.49
  • Short Ratio: 13.25
 
Frequently Asked Questions for Spectrum Pharmaceuticals (NASDAQ:SPPI)

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Tuesday, May, 2nd. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The business earned $29.10 million during the quarter, compared to analyst estimates of $32.23 million. Spectrum Pharmaceuticals had a negative net margin of 62.39% and a negative return on equity of 24.06%. View Spectrum Pharmaceuticals' Earnings History.

Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1 year target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $9.00 to $11.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.

What are analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Spectrum focuses in the fields of hematology and oncology. The company's progress with its lead pipeline candidate Rolontis has been quite impressive. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock adversely. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares outperformed the Medical Drugs industry so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/5/2017)
  • 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:

  • Rajesh C. Shrotriya M.D., Chairman of the Board, Chief Executive Officer
  • Joseph W. Turgeon, President, Chief Operating Officer
  • Kurt A. Gustafson, Chief Financial Officer, Executive Vice President
  • Luigi Lenaz M.D., Lead Independent Director
  • Gilles R. Gagnon, Director
  • Raymond Wayne Cohen, Independent Director
  • Stuart M. Krassner, Independent Director
  • Anthony E. Maida III, Ph.D., Independent Director

Who owns Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.14%), Louisiana State Employees Retirement System (0.04%), Capstone Asset Management Co. (0.02%) and State of Alaska Department of Revenue (0.02%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Bank of Montreal Can. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy Spectrum Pharmaceuticals stock?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $8.02.


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Spectrum Pharmaceuticals (NASDAQ:SPPI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (24.69% upside)

Analysts' Ratings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Jefferies Group LLCSet Price TargetBuy$9.00LowView Rating Details
5/6/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank Of CanadaSet Price TargetBuy$11.00 -> $10.00N/AView Rating Details
8/18/2015Roth CapitalReiterated RatingNeutral$6.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Earnings History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.22)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)
2017 EPS Consensus Estimate: ($0.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20172($0.27)($0.23)($0.25)
Q3 20172($0.25)($0.25)($0.25)
Q4 20172($0.27)($0.24)($0.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 67.35%
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Latest Headlines for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Source:
DateHeadline
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 25 at 8:40 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to Announce -$0.26 EPS
www.americanbankingnews.com - July 25 at 9:03 AM
americanbankingnews.com logoHead-To-Head Comparison: Spectrum Pharmaceuticals (SPPI) versus Nabriva Therapeutics AG (NBRV)
www.americanbankingnews.com - July 20 at 8:22 PM
nasdaq.com logoSUPN Crosses Above Average Analyst Target
www.nasdaq.com - July 13 at 9:49 AM
businesswire.com logoAlnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
www.businesswire.com - July 8 at 7:27 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 5 at 12:12 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 1:44 PM
americanbankingnews.com logo Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.20 Million
www.americanbankingnews.com - June 30 at 11:23 AM
americanbankingnews.com logo Brokerages Expect Spectrum Pharmaceuticals, Inc. (SPPI) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - June 29 at 12:38 AM
streetinsider.com logoSpectrum Pharma (SPPI) Highlights Results of Combination Study of FOLOTYN Plus Romidepsin Presented at ICML - StreetInsider.com
www.streetinsider.com - June 19 at 9:29 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting
finance.yahoo.com - June 19 at 9:29 AM
reuters.com logoBRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting
www.reuters.com - June 17 at 6:21 AM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - June 11 at 7:52 AM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - June 6 at 1:04 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 12:47 PM
americanbankingnews.com logo Analysts Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.20 Million
www.americanbankingnews.com - June 4 at 7:34 AM
americanbankingnews.com logo-$0.26 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter
www.americanbankingnews.com - June 2 at 10:30 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
finance.yahoo.com - June 2 at 8:01 AM
finance.yahoo.com logoSpectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th
finance.yahoo.com - May 30 at 9:01 AM
finance.yahoo.com logoSpectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
finance.yahoo.com - May 16 at 9:02 AM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 11 at 4:40 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 3:32 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.2 Million
www.americanbankingnews.com - May 11 at 11:36 AM
americanbankingnews.com logo Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - May 9 at 12:30 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. to Post Q2 2017 Earnings of ($0.27) Per Share, Jefferies Group Forecasts (SPPI)
www.americanbankingnews.com - May 5 at 7:46 AM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. Forecasted to Post Q2 2017 Earnings of ($0.23) Per Share (SPPI)
www.americanbankingnews.com - May 5 at 7:46 AM
americanbankingnews.com logoFY2020 EPS Estimates for Spectrum Pharmaceuticals, Inc. (SPPI) Raised by Jefferies Group
www.americanbankingnews.com - May 4 at 8:04 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - May 3 at 10:54 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Earns Media Impact Rating of 0.14
www.americanbankingnews.com - May 3 at 10:44 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 5:00 PM
fool.com logoWhy Spectrum Pharmaceuticals Stock Is Sinking Today
www.fool.com - May 3 at 1:19 PM
seekingalpha.com logoSpectrum Pharmaceuticals -7% off Q1 earnings miss
seekingalpha.com - May 2 at 7:43 PM
marketbeat.com logoSpectrum Pharma reports 1Q loss
marketbeat.com - May 2 at 6:13 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update - Yahoo Finance
finance.yahoo.com - May 2 at 5:48 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
finance.yahoo.com - May 2 at 5:48 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - April 30 at 10:42 AM
finance.yahoo.com logoSpectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
finance.yahoo.com - April 27 at 3:34 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Earns News Impact Rating of 0.22
www.americanbankingnews.com - April 25 at 7:07 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Receiving Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 10:18 PM
americanbankingnews.com logo Analysts Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) to Post -$0.20 EPS
www.americanbankingnews.com - April 18 at 4:31 PM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. (SPPI) Short Interest Update
www.americanbankingnews.com - April 16 at 12:20 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Given News Impact Rating of 0.44
www.americanbankingnews.com - April 16 at 7:34 AM
finance.yahoo.com logoSpectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SPPI-US : April 14, 2017
finance.yahoo.com - April 14 at 12:27 PM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 13 at 5:03 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- La Jolla Pharma ... - PR Newswire (press release)
www.prnewswire.com - April 10 at 7:28 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- La Jolla Pharma, Spectrum Pharma, Advaxis, and Aevi Genomic
www.bizjournals.com - April 10 at 9:04 AM
americanbankingnews.com logoSpectrum Pharmaceuticals, Inc. Forecasted to Post Q2 2017 Earnings of ($0.25) Per Share (SPPI)
www.americanbankingnews.com - April 10 at 7:33 AM
finance.yahoo.com logoETFs with exposure to Spectrum Pharmaceuticals, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 10:05 PM
americanbankingnews.com logoEquities Analysts Set Expectations for Spectrum Pharmaceuticals, Inc.'s FY2021 Earnings (SPPI)
www.americanbankingnews.com - April 7 at 5:45 PM
businesswire.com logoSpectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
www.businesswire.com - April 4 at 8:33 AM

Social

Chart

Spectrum Pharmaceuticals (SPPI) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff